Cancer, an international interdisciplinary journal of the American Cancer Society, publishes high-impact, peer-reviewed original articles and solicited content on the latest clinical research findings. Spanning the breadth of oncology disciplines, Cancer delivers something for everyone involved in cancer research, risk reduction, treatment, and patient care.

Featured Content

Skip slideshow
  • The journal is pleased to announce Direct to Cancer, a new manuscript submission pathway that will offer an accelerated review process for potentially practice-changing manuscripts that have been rejected after peer review by high-impact general medicine or oncology journals for reasons of scope or priority.

    Read an introductory editorial about Direct to Cancer.

  • Cancer is pleased to present “Top Advances of the Year,” a new series of articles that highlight cutting-edge advances in cancer research for specific organ-site cancers. These articles reflect the opinions of the leaders in the respective areas and are intended to keep the readers apprised on major progress. The authors provide a succinct review on the top advances and their key “take-home messages” from the specific studies discussed; the readers are referred to the original articles for additional details.

     Explore the latest Top Advances of the Year articles here.

  • The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate to provide annual updates on cancer occurrence and trends in the United States.

    The latest Annual Report to the Nation on the Status of Cancer is now available. Click below to access the article.

    Annual Report to the Nation on the Status of Cancer, Featuring State-Level Statistics after the Onset of the COVID-19 Pandemic

Articles

Twenty‐five years without progress: The enduring challenge of soft tissue sarcomas

  •  21 May 2025

Abstract

Soft tissue sarcomas (STSs) have shown minimal survival improvement over the past 25 years, unlike gastrointestinal stromal tumors, which have achieved significant gains as a result of targeted therapies. This study highlights the urgent need for focused research and innovation to address the stagnant therapeutic landscape of STSs.

free access

Issue Information

  •  21 May 2025
More articles
free access

Index for rating diagnostic tests

  •  32-35
  •  1950
First page image
free access

Osteosarcoma incidence and survival rates from 1973 to 2004

  •  1531-1543
  •  5 February 2009

Abstract

This comprehensive, population-based description of osteosarcoma identified important differences in incidence, survival, pathologic subtype, and anatomic site among age groups and quantified the impact of osteosarcoma in Paget disease or as a second cancer on incidence and mortality rates. These findings may have implications for understanding the biology and epidemiology of osteosarcoma.

free access

Congestive heart failure in patients treated with doxorubicin

  •  2869-2879
  •  19 May 2003

Abstract

This analysis suggests that doxorubicin-related congestive heart failure (CHF) occurs more frequently and at a lower cumulative dose than previously reported. Left ventricular ejection fraction does not appear to be an accurate predictor of CHF in doxorubicin-treated patients.

More articles
Open access

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

  • Cancer
  •  4423-4431
  •  28 July 2020

Abstract

The Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology developed clinical practice guidelines for the management of mucositis, with the first edition published in 2004 and periodically updated. This summary presents the 2019/2020 guidelines update, which is based on a systematic review, and generates a tool that will help clinicians to select evidence-based interventions.

Open access

Burden of 30 cancers among men: Global statistics in 2022 and projections for 2050 using population‐based estimates

  • Cancer
  •  3708-3723
  •  12 August 2024

Abstract

In 2022, notable cancer disparities were observed between men’s age groups and between countries/territories, and these disparities are projected to widen by 2050. Strengthening health system infrastructure, improving access to universal health coverage, and multidisciplinary approaches are essential for narrowing existing and projected cancer disparities, ultimately ensuring cancer equity in men worldwide.

free access

Patterns of high‐dose morphine use in a home‐care hospice service

  • Cancer
  •  1473-1477
  •  27 July 2004

Abstract

The use of morphine by patients in a home-care hospice setting was found to be safe, even with high doses, and was not associated with shorter survival. The use of high-dose morphine should not be a barrier to providing palliative terminal care for outpatients with advanced-stage cancer.

free access

The ever‐increasing importance of cancer as a leading cause of premature death worldwide

  • Cancer
  •  3029-3030
  •  4 June 2021

Abstract

Cardiovascular disease and cancer are now the leading causes of premature death in the majority of countries worldwide, and cancer is likely to surpass cardiovascular disease as the leading causes of death at ages 30-70 in most countries over the course of this century. Governments must factor in these transitions in formulating and implementing their cancer and noncommunicable disease plans and tailor cost-effective measures to the local disease profile.

Open access

The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types

  • Cancer
  •  3192-3201
  •  13 May 2020

Abstract

This review provides an overview of immuno-oncology therapies and those in development. It specifically focuses on bispecific T-cell engager (BiTE) technology, its mechanism of action, types of cancer in which it has had success, half-life-extended BiTE molecules, and their potential as an off-the-shelf, targeted immunotherapy.

More articles

Enjoy free-to-read articles from the latest issues of Cancer.

Free to Read

Serum of interleukin‐6 and procalcitonin as early diagnostic markers for the identification of poor hematopoietic reconstitution following allogeneic hematopoietic stem cell transplantation

Abstract

Poor hematopoietic reconstitution (PHR) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is significantly associated with adverse patient outcomes. Interleukin-6 and procalcitonin can predict PHR following allo-HSCT.

Free to Read

The relationship between cardiometabolic abnormalities and mortality in the Women’s Health Initiative: A comparison of associations among women with cancer to women without cancer

Abstract

Preexisting cardiovascular abnormalities including high waist circumference (≥88 cm), hypertension (>130/85 mm Hg), and self-reported history of diabetes and/or elevated cholesterol are an important predictor of outcomes among both women with and without cancer in the Women’s Health Initiative.

Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a‐rearranged acute myeloid leukemia

Abstract

The authors investigated the prognostic impact of pretransplantation molecular measurable residual disease in adult patients with acute myeloid leukemia who had lysine methyltransferase 2a rearrangements. The results demonstrated that the presence of lysine methyltransferase 2a-rearranged measurable residual disease independently predicts posttransplantation mortality and relapse risk, providing a basis for tailored therapeutic strategies in high-risk patients.

Bereaved parent preferences on quality end‐of‐life care for children with cancer in the South

Abstract

Regardless of race, families preferred comfort care over medically intense end-of-life care while also wanting to continue chemotherapy. Parents prioritized quality care that allowed flexibility and focused on quality time with their child. Regular access to their care team was emphasized more than a specific location of death.

Access to primary care and mortality in excess for patients with cancer in France: Results from 21 French Cancer Registries

Abstract

This study aims to examine the association of access to primary care with mortality in excess of patients with the 10 most frequent cancers in France, while controlling for socioeconomic deprivation. Patients living in areas with less access to primary care had a greater mortality in excess for some very common cancer sites like breast (women), lung (men), liver (men and women), and colorectal cancer (men), representing 46% of patients diagnosed in our sample.

Association of clonal hematopoiesis and mosaic chromosomal alterations with solid malignancy incidence and mortality

Abstract

In the Women’s Health Initiative Trans-Omics for Precision Medicine study, participants with clonal hematopoiesis of indeterminate potential (CHIP) had higher breast cancer incidence and a higher colorectal cancer mortality than women without CHIP. The presence of autosomal mosaic chromosomal alterations with >5% cell fraction was associated with higher incidence of breast cancer but no other cancers.

Insulin resistance during androgen deprivation therapy in men with prostate cancer

Abstract

In this prospective study of hormone-naive men who were eugonadal and did not have diabetes, 24 weeks of androgen deprivation therapy (ADT) for prostate cancer (PCa) was not associated with worsening of hepatic or skeletal muscle insulin resistance despite a substantial increase in fat mass. These findings have relevance for both physicians and patients when determining treatment for PCa and suggest that a short course of ADT may not worsen metabolic risk in patients without pre-existing diabetes.

Top advances of the year: Targeted therapy for lung cancer

Abstract

Several clinical trials published this past year have contributed to significant advances in thoracic oncology. Here, the focus is on targeted therapy advances reported in 2023 that are impacting clinical decision-making in everyday practice.

Posttransplant cyclophosphamide versus anti‐thymocyte globulin versus combination for graft‐versus‐host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party

Abstract

This study analyzed 3649 adult acute myeloid leukemia (AML) patients undergoing haploidentical stem cell transplantation (haplo-SCT) with either posttransplant cyclophosphamide (PTCy), anti-thymocyte globulin (ATG), or their combination, and showed that ATG alone had worse outcomes compared to PTCy, but combining PTCy and ATG significantly reduced acute graft-vs-host disease (GVHD) rates without affecting transplant outcomes. This suggests the PTCy and ATG combination could be a superior GVHD prophylaxis strategy in haplo-SCT for AML.

Recent issues

Latest news